Expression of Endothelin-1, Endothelin Receptor-A, and Endothelin Receptor-B in facial melasma compared to adjacent skin

da Silva, Carolina; Miot, Hélio; Grassi, Tony Fernando; Dias-Melício, Luciane Alarcão; Santos, Leandro; Espósito, Ana Cláudia Cavalcante

doi:10.2147/ccid.s402168

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Some antioxidants have shown mild improvement of melasma, as both local and systemic oxidative stress are acknowledged as pathogenic factors and are associated with disease severity. [1][2][3][4][5] Oral pycnogenol has shown an additional efficacy of 15% to triple combination in its treatment. 6 Melatonin is a circadian rhythm regulator with antioxidant properties, acting as a potent scavenger of free radicals and stimulating other antioxidant enzymes (e.g.…”

Section: Efficacy Of Oral 5 Mg Melatonin In the Treatment Of Facial M...mentioning

confidence: 99%

Efficacy of oral 5 mg melatonin in the treatment of facial melasma in women: A double‐blind, randomized, placebo‐controlled clinical trial

Holanda,

de Almeida Corrêa Alfredo,

Cassiano

et al. 2024

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Section: Efficacy Of Oral 5 Mg Melatonin In the Treatment Of Facial M...mentioning

confidence: 99%

Efficacy of oral 5 mg melatonin in the treatment of facial melasma in women: A double‐blind, randomized, placebo‐controlled clinical trial

Holanda,

de Almeida Corrêa Alfredo,

Cassiano

et al. 2024

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Sequential therapy with topical clobetasol for 14 days followed by hydroquinone versus hydroquinone alone in facial melasma treatment: a randomized, double‐blind, controlled clinical trial

de Amorim,

Barbosa,

Cassiano

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundClobetasol has demonstrated remarkable results in treating melasma within a short time frame; however, its use is limited because of the risk of local side effects. To date, there is no controlled trial on sequential clobetasol/hydroquinone for melasma. This study aimed to investigate the tolerability and efficacy of 0.05% clobetasol followed by 4% hydroquinone (CLOB‐HQ) in comparison to the isolated use of 4% hydroquinone (HQ).MethodsA double‐blinded, randomized clinical trial involving 50 women with facial melasma was performed. They were directed to apply 0.05% clobetasol every night for 14 days, followed by 4% hydroquinone for 46 days (CLOB‐HQ group), or the use of hydroquinone for 60 days (HQ group). Evaluations were carried out at inclusion, and after 14 and 60 days of treatment, measuring modified Melasma Area and Severity Index (mMASI), Melasma Quality of Life scale (MELASQoL), and colorimetry. The Global Aesthetic Improvement Scale (GAIS) was assessed by a blinded evaluator.ResultsThere was no difference in the main outcomes at D14 and D60 (P > 0.1). For CLOB‐HQ, the mean (CI 95%) reduction in mMASI was 13.2% (5.1–21.3%) and 43.1% (32.2–54.0%) at D14 and D60, and for HQ, they were 10.6% (5.9–27.5%) and 44.8% (33.2–52.3%). The MELASQoL, colorimetric luminosity, and GAIS showed a progressive improvement for both groups despite no difference between them. No severe side effects were identified. No cases of telangiectasias, atrophy, or perioral dermatitis were associated with the use of CLOB.ConclusionThe sequential CLOB‐HQ regimen was safe and well tolerated, even though its efficacy was not different from HQ after 14 or 60 days of treatment. Based on these findings, the use of clobetasol 14 days before hydroquinone is not advisable for the treatment of melasma.

show abstract

Efficacy and Safety of Nicotinamide 10%, Associated with Magnesium Ascorbyl Phosphate 5% and Hyaluronic Acid 5%, Compared to Hydroquinone 4% in Women with Facial Melasma: A Randomized, Double-Blind, Controlled Clinical Trial.

Barbosa,

de Amorim,

Cassiano

et al. 2024

CCID

View full text Add to dashboard Cite

Background Nicotinamide has demonstrated efficacy in the treatment of melasma. Topical antioxidants and humectants may enhance its performance. Currently, there is no controlled trial on the combination of 10% nicotinamide, 5% magnesium ascorbyl phosphate, and 5% hyaluronic acid, a dermo-cosmetic compound, in comparison to 4% hydroquinone for the treatment of melasma. This study aimed to explore the tolerability and efficacy of the association of the combined product versus hydroquinone. Methods A randomized, double-blind trial involving women with facial melasma was conducted. Participants were instructed to apply the combined product (NIC group) twice daily or 4% hydroquinone for 60 days (HQ group) at night and placebo in the morning. Evaluations were performed at inclusion, after 14 and 60 days of treatment, measuring the modified Melasma Area and Severity Index (mMASI), Melasma Quality of Life Scale (MELASQoL), and colorimetric luminosity. The Global Aesthetic Improvement Scale (GAIS) was assessed by a blinded evaluator. Results Both interventions led to a progressive improvement in mMASI, MELASQoL, and GAIS, without a difference between them on D14 and D60 (p>0.2). For NIC, the mean reduction (95% CI) in mMASI was 16% (8–24%) on D14 and 32% (23–41%) on D60, while for HQ, it was 10% (7–24%) on D14 and 43% (34–52%) on D60. Reduction in colorimetric luminosity was greater in the HQ group at D60 (p=0.01). No serious side effects were identified. Of the initially included 50 patients, one was lost to follow-up in the HQ group on D60, and one withdrew consent from the NIC group, both unrelated to treatment. Conclusion The association of 10% nicotinamide, 5% magnesium ascorbyl phosphate, and 5% hyaluronic acid was safe and well-tolerated, although its overall clinical efficacy was numerically inferior to 4% hydroquinone. This regimen can be considered for patients with poor tolerability to hydroquinone. Clinical Trial Registration #RBR-4mkfmr8.

show abstract

Expression of Endothelin-1, Endothelin Receptor-A, and Endothelin Receptor-B in facial melasma compared to adjacent skin

Cited by 3 publications

References 49 publications

Efficacy of oral 5 mg melatonin in the treatment of facial melasma in women: A double‐blind, randomized, placebo‐controlled clinical trial

Efficacy of oral 5 mg melatonin in the treatment of facial melasma in women: A double‐blind, randomized, placebo‐controlled clinical trial

Sequential therapy with topical clobetasol for 14 days followed by hydroquinone versus hydroquinone alone in facial melasma treatment: a randomized, double‐blind, controlled clinical trial

Efficacy and Safety of Nicotinamide 10%, Associated with Magnesium Ascorbyl Phosphate 5% and Hyaluronic Acid 5%, Compared to Hydroquinone 4% in Women with Facial Melasma: A Randomized, Double-Blind, Controlled Clinical Trial.

Contact Info

Product

Resources

About